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Central picture 59 
 60 
 61 
 62 
Legend: Cumulative probability of all-cause in-hospital mortality  63 
Time varying outcome with shaded areas showing 95% confidence intervals based on 1-Kaplan-Meier 64 
estimation of TAVI (transcatheter aortic valve implantation) vs. SAVR (surgical aortic valve replacement); HR = 65 
Hazard ratio.  66 
 67 
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Central message 69 
In patients with high-surgical risk, our study using real-world evidence shows TAVI to be 70 
associated with a greater risk of mortality after 1 year which is sustained up to 5 years  71 
 72 
Perspective statement 73 
The extension of TAVI indications in patients other than those with high or prohibitive- 74 
surgical risk should be cautious until further data, either based on RCTs or real-world 75 
evidence, are made available to inform on the relative long-term effectiveness of TAVI 76 
compared to SAVR. 77 
  78 
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Structured Abstract (241 words) 79 
 80 
Objective: To compare the clinical outcomes and direct costs at 5 years between TAVI or 81 
SAVR using real-world evidence. 82 
Methods: We performed a nationwide longitudinal study using data from the French Hospital 83 
Information System over 2009-2015. We matched inside hospitals two cohorts of adults who 84 
underwent TAVI or SAVR in 2010 on propensity score based on patients characteristics. 85 
Outcomes analysis included mortality, morbidity, and total costs and with a maximum 60-86 
month follow-up. Clinical outcomes were compared between cohorts using Hazard Ratios 87 
(HR) estimated from Cox proportional hazards model for all-cause death, and from Fine and 88 
Gray’s competing risk model for morbidity.  89 
Results: Based on a cohort of 1598 patients (799 in each group) from 27 centers, a higher risk 90 
of death was observed after 1 year with TAVI compared to SAVR (16.8% vs. 12.8% 91 
respectively; HR 1.33, 95%CI 1.02-1.72) and was sustained up to 5 years (52.4% vs. 37.2%; 92 
HR 1.56, 95%CI 1.33-1.84). At 5 years, the risk of stroke was increased (HR 1.64, 95%CI 93 
1.07-2.54) as was myocardial infarction (HR 2.30, 95%CI 1.12-4.69) and pacemaker 94 
implantation (HR 2.40, 95%CI 1.81-3.17) after TAVI. The hospitalization costs per patient at 95 
5 years were €69,083 after TAVI and €55,687 after SAVR (p<0.001).  96 
Conclusions: In our study, high-risk patients after TAVI harbor a greater risk of mortality and 97 
morbidity at 5 years compared to SAVR and higher hospitalizations costs. Those results 98 
should encourage to be more cautious before enlarging the indications of TAVI. 99 
  100 
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Introduction 101 
More than 15 years after the first-in-man case,1 transcatheter aortic valve implantation (TAVI) 102 
continues to revolutionize the management of severe aortic stenosis and has become over time 103 
a routinely performed procedure in many cardiac centers worldwide. In early 2014, more than 104 
100,000 had been performed.2 While the benefit of TAVI was initially demonstrated in 105 
patients ineligible or at high-surgical risk,3, 4 a growing number of studies have evaluated 106 
TAVI in patients with low-to-intermediate risk.5, 6 This has contributed to the currently 107 
observed trend toward enlarged indications of TAVI in patients that would otherwise undergo 108 
surgical aortic valve replacement (SAVR). Several randomised controlled trial (RCTs) 109 
conducted among carefully selected populations have shown promising results on the clinical 110 
effectiveness and safety of TAVI compared to surgery.4, 5, 7 Conversely, evidence from real-111 
world data indicate a better outcome with surgery compared to TAVI.8 Overall, the largest 112 
reported cohorts have a follow-up limited to one to three years in maximum9, 10 which is 113 
insufficient to provide a long-term view after aortic valve replacement (AVR).  114 
This nationwide study aimed to compare the long-term clinical outcomes and costs between 115 
patients undergoing TAVI and SAVR.  116 
 117 
Material and Methods 118 
Study design and participants  119 
We conducted a propensity-matched cohort study based on the French Medical Information 120 
System (programme de médicalisation des systèmes d’information [PMSI]). The PMSI is a 121 
large hospital database with prospectively collected data from all public and private hospitals 122 
in France. The database is routinely implemented for the purpose of care reimbursement 123 
leading to very strong accuracy and exhaustive collection of the data. As a consequence no 124 
patients were lost to follow-up during the considered period. Moreover, the PMSI has a 125 
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system of coding with strict variable definitions and a subset of records audited on a regular 126 
basis in order to avoid an excessive high rates of coding errors. Inpatient’s stays are converted 127 
into one Diagnosis-Related-Group (DRG) based on standard discharge abstracts containing 128 
compulsory information about the patient, primary and secondary diagnoses, using the 129 
International Classification of Diseases (10th revision - ICD-10), as well as procedural codes 130 
associated with the care provided.  131 
We selected all adults who underwent TAVI or SAVR in French institutions between 1, 132 
January, 2010 and 31, December, 2010. In order to homogenize study population, we only 133 
selected cases with a main diagnosis of heart failure, rheumatic or nonrheumatic aortic valve 134 
disease (ICD-10 codes I06*, I35*, or I50*). Patients <18 years, having experienced 135 
ambulatory care, or with data inaccuracies were not retained in final cohorts. Within the index 136 
hospitalization stay, we extracted patients’ demographics and socioeconomic characteristics, 137 
co-morbidities according to Charlson and/or Elixhauser algorithms11, the type and emergency 138 
context of surgical procedure, and length of stay. We subsequently used patient unique 139 
anonymous number in order to link his/her stays in acute and rehabilitation care, allowing the 140 
extraction of hospitalization-related data from 12 months preceding TAVI and SAVR to a 141 
maximum of 60 months thereafter.  142 
 143 
Outcomes 144 
The primary endpoint was in-hospital mortality from the index hospitalization up to five years 145 
following TAVI or SAVR. Other outcomes included the occurrence of postoperative 146 
admission in intensive (≥2 nights) or critical care unit (≥5 nights), reoperation, stroke, 147 
myocardial infarction, or pacemaker implantation.   148 
Economic evaluation was performed from the hospital perspective based on the total number 149 
of hospitalization stays, days, and costs over 5 years in acute or rehabilitation care. We valued 150 
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in Euros (€) the in-hospital medical resources consumptions using average expenditures as 151 
observed in the national cost scale for the medicine, surgery, and obstetrics sector.  152 
 153 
Statistical analysis  154 
To control for the nonrandom assignment of patients to one of the two procedures, we formed 155 
matched pairs of TAVI and SAVR patients using propensity scores. First, propensity scores 156 
were estimated as the predicted probability of a patient undergoing TAVI using a logistic 157 
regression model including the following covariates: sex, age (continuous, with linear, 158 
quadratic and cubic terms), household income (continuous), number of days spent in acute 159 
care hospitalizations the year before the index stay (continuous, with linear, quadratic and 160 
cubic terms), emergency procedure, and a selection of comorbidities (i.e. congestive heart 161 
failure, cardiac arrhythmia, pulmonary circulation disorder, peripheral vascular disease, 162 
hypertension, chronic pulmonary disease, diabetes, renal disease, liver disease, obesity, 163 
myocardial infarction, and cerebrovascular disease). We then matched patients with the 164 
closest propensity score inside hospital to control for confounders at hospital level, using a 165 
greedy 1:1 algorithm without replacement and requiring that the logit of the propensity score 166 
of a patient who underwent TAVI and one who underwent SAVR be within 0.20 standard 167 
deviations of one another. Standardized differences were used to assess the degree of balance 168 
between the matched groups for baseline characteristics. An absolute standardized difference 169 
of ≤0.10 was chosen to indicate a negligible difference in the mean or prevalence of a variable 170 
between groups. Balance for continuous variables was also assessed with graphical methods 171 
(side-by-side boxplots, empirical cumulative distribution functions, empirical QQ-plots) to 172 
compare the distributions across the two groups. Sensitivity analysis was conducted for the 173 
main outcomes (all-cause death and costs) with 1:1 nearest neighbor matching with 174 
replacement within caliper of 0.20 standard deviation of the logit of the propensity score, with 175 
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the inclusion of weights in the outcome models (TAVI patients were weighted at 1 and the 176 
weight for a SAVR patient was the number of times it was matched to a TAVI patient). 177 
 178 
Categorical variables were presented using absolute and relative frequencies and continuous 179 
variables were presented using medians and interquartile ranges. Estimates were accompanied 180 
with the corresponding 95% CI and p-values of less than 0.05 were considered to indicate 181 
statistical significance.  182 
 183 
Clinical outcomes were assessed as time-to-event variables, and were evaluated at different 184 
time points t (1 month, 6 months, then yearly up to 5 years after index procedure). Cumulative 185 
probabilities of events over time were estimated with the non-parametric 1-Kaplan-Meier 186 
estimator for all-cause death, and with the non-parametric Cumulative Incidence Functions 187 
estimator using competing risk of death for postoperative stay in intensive or critical care unit, 188 
reoperation, stroke, myocardial infarction, and pacemaker. To compare the effect of procedure 189 
(TAVI vs. SAVR), Hazard Ratios (HR) were estimated between time 0 and time t, from Cox 190 
proportional hazards model for all-cause death, and from Fine and Gray’s model using 191 
competing risk of death for other clinical outcomes, with robust variance estimator to account 192 
for clustering within matched pairs. A sensitivity analysis was performed for the main clinical 193 
outcome (all-cause death) with a nested frailty model to take into account the two hierarchical 194 
levels of clustering (matched pairs nested within hospitals). 195 
 196 
Health care utilization (number of hospitalization stays, days, and costs) were assessed as 197 
count variables, and were evaluated at different time points t. The rate of health care 198 
utilization per patient-year was the total number of health care utilization in each procedure 199 
group divided by the total follow-up duration (date of the procedure until the date of death or 200 
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end of the study period) of all patients in that group between time 0 and time t. The 201 
consequent rate ratio (RR) comparing TAVI to SAVR was estimated using Generalized 202 
Estimating Equations (GEE) with a log link, a Poisson distribution, and the log of the follow-203 
up time as an offset. Robust standard errors were estimated using an independent or 204 
exchangeable working correlation structure and clustering on matched-pairs to account for 205 
over dispersion (dependency within matched pairs and within patients experiencing repeated 206 
events). A sensitivity analysis was performed for the main economic outcome (costs) with a 207 
multilevel Poisson regression model to take into account the two hierarchical levels of 208 
clustering (matched pairs nested within hospitals). Mean cumulative numbers of health care 209 
utilization per person at time t were estimated by multiplying the predicted rate by t. 210 
Sensitivity analyses were performed with a Negative Binomial distribution for all economic 211 
outcomes and with a Gamma distribution for costs, providing rate ratio estimations. 212 
 213 
Data manipulation and analyses were performed using SAS (version 9.4; SAS Institute Inc., 214 
Cary, NC) and R (version 3.3.2; R Core Team) softwares. 215 
 216 
Ethics approval:  217 
This study was strictly observational and we used anonymous data retrospectively. Therefore, 218 
in accordance to the French regulation on “non-interventional clinical research”, the written 219 
informed consent from the participants or the authorization from an ethical committee was not 220 
required. 221 
 222 
 223 
Results 224 
 225 
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Participants/descriptive data  226 
During Year 2010, 1334 patients underwent TAVI and 6,695 patients underwent SAVR at 27 227 
French hospitals. After applying the selection and matching criteria, 799 pairs of patients were 228 
retained in final analysis (Supplemental 1). Cohorts’ baseline characteristics are listed in 229 
Table 1 with negligible difference between those (evolution pre and post-matching is 230 
presented in the Supplemental 2), and distribution of the propensity scores pre and post-231 
matching are represented in the Supplemental 5. 232 
 233 
Short-term clinical outcomes  234 
The risk of hospital death from any cause at 30 days, 6 months, and 1 year was respectively 235 
7.5%, 12.7%, and 16.8% in the TAVI group, and 6.6%, 10.0%, and 12.8% in the SAVR 236 
group, and was not different between both groups at 30 days and 6 months (respectively HR 237 
1.15, 95%CI 0.79-1.68; 1.29, 95%CI 0.96-1.73) but was higher after TAVI at 1 year (HR 238 
1.33, 95%CI 1.02-1.72). 239 
At 1 year, there was no significant difference in the occurrence of reoperation (1.9% with 240 
TAVI vs. 0.9% with SAVR) or myocardial infarction (0.6% with TAVI vs. 0.1% with 241 
SAVR), but the risk of stroke was higher after TAVI (2.4% vs. 0.9% respectively; HR 2.73, 242 
95%CI 1.14-6.53) as was the risk of new pacemaker implantation (14.5% vs. 4.9% 243 
respectively; HR 3.19, 95%CI 2.23-4.56).  244 
 245 
Long-term clinical outcomes  246 
The cumulative probabilities and HR of each clinical outcome from 1 to 5 years are presented 247 
in Table 2, accompanied with the cumulative probability curves for death (Central figure) and 248 
for the other clinical outcomes (Supplemental 6). 249 
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A higher risk of death was observed 2 years after TAVI compared to SAVR (24.2% vs. 16.8% 250 
respectively; HR 1.47, 95%CI 1.17-1.84) and sustained up to 5 years (52.4% vs. 37.3% 251 
respectively; HR 1.56, 95%CI 1.33-1.84). 252 
At 5 years, there was a trend toward a higher risk of reoperation after TAVI compared to 253 
SAVR (2.3% vs. 1.1%: HR 2.01, 95%CI 0.90-4.50), while the risk of stroke significantly 254 
increased (6.9% vs. 4.3% respectively; HR 1.64, 95%CI 1.07-2.54), as was myocardial 255 
infarction (3.1% vs. 1.4% respectively; HR 2.30, 95%CI 1.12-4.69), or new pacemaker 256 
implantation (20.4% vs. 9.3% respectively; HR 2.40, 95%CI 1.81-3.17).  257 
 258 
Hospitalization data and cost evaluation  259 
Hospitalization data and cost evaluation up to 5 years after the procedure are presented in 260 
Table 3 and figure 1. At 1 year, the mean cumulative hospitalization costs per patient were 261 
€42,238 after TAVI and €35,128 after SAVR (RR 1.20, 95%CI 1.13-1.28). The increased cost 262 
with TAVI was mainly attributed to the procedure performed during the index stay and was 263 
sustained up to 5 years (€69,083 vs.  €55,687 respectively; RR 1.24, 95%CI 1.13-1.36). The 264 
mean cumulative numbers of hospitalization stays and of days of hospitalization per patient 265 
were similar at any time in both groups, except for the mean cumulative number of days of 266 
hospitalization at 1 year which was lower after TAVI (RR 0.86, 95%CI 0.79-0.94). 267 
 268 
Sensitivity analysis for the main outcomes 269 
Matching with replacement resulted in 1089 matched-pairs of TAVI and SAVR and the same 270 
trends for all-cause death and costs, although effects were attenuated and results at 1 year up 271 
to 3 years became non-significant (Supplemental 7). 272 
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In the cohort matched without replacement, the nested frailty model for all-cause death 273 
resulted in very similar effects (Supplemental 8), whereas the multilevel Poisson regression 274 
for costs did not converge.  275 
 276 
 277 
Discussion 278 
Principal findings  279 
We have used real-world data from a nationwide database including 100% of the cases during 280 
the considered period to compare the long-term clinical outcomes between TAVI and SAVR 281 
in two propensity score matched cohorts of patients. Our findings showed an increased risk of 282 
death after TAVI at 1 year that increased up to 50% at 5 years. There were also a much higher 283 
risk of stroke, myocardial infarction and pacemaker implantation after TAVI with higher 284 
cumulated costs relating with the index hospitalisation stay. 285 
 286 
Comparison with other studies 287 
The entire TAVI population (n=1274) that we identified from the database was also part of 288 
the France 2 French registry that enrolled 3195 high-risk patients (mean Logistic Euroscore 289 
21% / 74% with a Logistic Euroscore ≥ 20%) between January 2010 and October 2011.3 290 
While the entire SAVR population had a lower risk compared to the entire TAVI population, 291 
we selected a cohort of patients with much higher risk profile within the entire SAVR 292 
population. Hence, we assume that matching between these populations allowed us to 293 
compare similar cohorts of high-risk patients. 294 
Our survival estimates are supported by a longer follow up and larger study sample than 295 
previous publications comparing the two procedures (Table 4). Among RCTs that included 296 
high-risk patients (Logistic Euroscore 18%-29%), there was no significant difference on the 297 
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risk of death at three years12 and five years.13 The results from our study in high-risk patients 298 
contrast greatly with those reported in these two RCTs. While our study outcomes after TAVI 299 
were comparable to those in the US COREVALVE RCT, the survival after SAVR was far 300 
better compared to US COREVALVE. Among the four published propensity-score 301 
matching (PSM) cohort analyses that selected high-risk patients, two studies10, 14 showed no 302 
difference in mortality after 1 year while two other studies reported a greater mortality with 303 
TAVI from the first year and up to  two15 or four 16 years of follow-up. This increase in 304 
mortality with TAVI compared to SAVR is consistent with our findings and has been recently 305 
emphasized in a meta-analysis of studies that used PSM.8 306 
The magnitude of the mortality-increase after TAVI compared to SAVR raises the question 307 
on the comparability of TAVI and SAVR cohorts matched using PSM and will be further 308 
discussed. However, we believe that the systematic presence of unidentified confounders 309 
within healthcare databases used across different country settings is unlikely.  310 
 311 
Although our study did only include high-risk patients, we also examined the published 312 
outcomes after TAVI or SAVR in people with intermediate-risk patients (Table 4) owing to 313 
the increase used of TAVI in this population. 314 
Three RCTs that included people with a lower surgical risk reported a similar risk of mortality 315 
but to date the follow-up is limited to a maximum of two-years.5, 17-19 Two other studies using 316 
PSM in people with similar risk-profile showed a higher risk of death after TAVI at 3 years. 9 317 
20 Conversely, Thourani et al.21 reported a reduced mortality after TAVI at 1 year but these 318 
latter results are however subject to caution given the presence of several major 319 
methodological flaws pertaining to the covariates that were included in the propensity score 320 
model.22  321 
 322 
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We have observed an increased risk of stroke at five years with TAVI compared to SAVR. 323 
We cannot provide interpretation of these findings based on data pertaining to onset of post-324 
procedural atrial fibrillation or use of anticoagulation regimen at follow-up. One might 325 
speculate that TAVI patients mostly received dual antiplatelet therapy with clopidogrel and 326 
aspirin while SAVR patients received mostly VKA or just aspirin for three months. However, 327 
in the absence of formal recommendations on anticoagulation management, we believe there 328 
are lots of variations across centers.    329 
 330 
Our study provides further information on hospital resource consumption between TAVI and 331 
SAVR. The cumulative costs were higher after TAVI while there were no differences at 5 332 
years regarding the number of stays or days consumed at hospital. Furthermore, the lower 333 
number of hospitalisations contrasts with the higher total costs at 1 year post-TAVI compared 334 
to SAVR, which can be explained by the cost of TAVI device during the index stay. Although 335 
our study was not designed as a cost-effectiveness evaluation, our results showing a reduced 336 
survival and higher costs with TAVI suggest that TAVI would be dominated by SAVR.  337 
 338 
Limitations 339 
Our study carries several limitations. We identified two cohorts of patients from the French 340 
PMSI database, which is increasingly used in health service research given the exhaustive 341 
collection of medical information at the whole country population. 23, 24 To control for the 342 
non-random assignment of patients between TAVI and SAVR procedures, we used 343 
propensity-score-matching-adjustment based on a high number of patient characteristics and 344 
with control for confounders at hospital level. The risk of bias with PSM studies is to omit 345 
some potential confounders that can alter the comparability of populations and therefore 346 
threaten the validity of outcome measures.25 The PMSI database does not enable to precisely 347 
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calculate the Euroscore because the clinical variables that are available are not strictly those 348 
listed or are not as accurately defined among the factors that are accounted for in the 349 
Euroscore calculation.  Because data granularity did not allow us to accurately describe every 350 
patients profile with respect to the surgical risk, we added the number of hospitalization days 351 
in acute care consumed the year preceding the index stay to account for unmeasured 352 
confounders. Among variables available within the PMSI database, we chose in our 353 
propensity-score based method those with the most clinical relevance to discriminate the 354 
mortality/morbidity risk of populations but also accounting for those with a sufficient degree 355 
of validity. We are aware that the PMSI database variables may also lack of granularity to 356 
account for factors such as patient frailty or the complexity of the procedure. 357 
A weakness of large hospital databases is the miscoding of diagnoses during hospital stays 358 
that can underestimate patient’s comorbidities.26 This issue is not specific to a disease area or 359 
to certain type of procedure and is more influenced by a strong coding variability between 360 
healthcare providers and across years. Given this, we matched pairs of patients who 361 
underwent either TAVI or SAVR inside the same hospital and over the same period. Hence, 362 
we believe there is no a priori reason that miscoding would be more prominent in one cohort 363 
than another and would alter their comparability. Another limitation relates to our inability to 364 
capture deaths occurring outside hospital, which means that the mortality rates might be 365 
slightly underestimated. However the rate of death occurring outside hospitals is today 366 
extremely rare and probably negligible. There might also have been an underreporting of 367 
adverse events as suggested by the low incidence of stroke, myocardial infarction, or 368 
permanent pacemaker implantation observed in this study. Again, this issue is not specific to 369 
certain procedure type and we assume that the relative occurrence of these events between 370 
TAVI and SAVI was adequately estimated. Finally, the selected cohorts were treated during 371 
Year 2010, that is seven years ago, and may therefore be less representative of contemporary 372 
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practices and outcomes related to TAVI in French centers since patients characteristics, 373 
devices, and experience of centers have surely evolved in recent years. However, this choice 374 
enabled to provide the longest ever reported follow-up of TAVI patients based on real-world 375 
data. 376 
 377 
Practical implications  378 
The 2017 guidelines from the European Society of Cardiology (ESC)27  have considered 379 
TAVI in patients who are suitable for SAVR as assessed by the Heart Team but also an 380 
alternative to surgery in people who are at increased surgical risk, the decision being made by 381 
the heart team according to each patient characteristics. Accounting for the results of the 382 
Partner 2 trial,5 the AHA/ACC recently updated guidelines have extended the indication of 383 
TAVI to intermediate surgical risk depending on patient-specific procedural risks, values, and 384 
preferences.28 Based on these updated guidelines, the trend toward an enlarged use of TAVI 385 
to lower surgical risk patients is likely to get amplified to a great extent. As previously 386 
emphasized, the results from Partner 2 that suggest the non-inferiority of TAVI and SAVR in 387 
intermediate-risk patients are only available at two years which is notably insufficient to 388 
evaluate the long-term effectiveness of TAVI compared to SAVR for which the outcomes is 389 
demonstrated beyond twenty years. Moreover, the results from Partner 25, along with those of 390 
Partner-high risk13, may be not representative of real-world clinical outcomes. Our results 391 
showed an increased risk of mortality for TAVI compared to SAVR using a large nationwide 392 
database providing real-word evidence over a long-term perspective. The implication of our 393 
findings is that the extension of TAVI in patients other than those with high or prohibitive- 394 
surgical risk should be cautious until further data, either based on RCTs or real-world 395 
evidence, are made available to inform on the relative long-term effectiveness of TAVI 396 
compared to SAVR.  397 
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 398 
 399 
Conclusions 400 
Our study showed that patients after TAVI, compared to those who underwent SAVR, harbor 401 
a greater risk of mortality and morbidity at 5 years, and had higher costs of hospitalizations. 402 
These results indicate that more data are needed before considering an enlargement of TAVI 403 
indications in people eligible to conventional surgery. 404 
  405 
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Figure legend: 503 
 504 
Figure 1: Mean Cumulative costs over time 505 
TAVI = transcatheter aortic valve implantation; SAVR = surgical aortic valve replacement. 506 
Predictions from GEE Poisson regression model. 507 
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Table 1- Baseline characteristics of patients post-matching 
 
 
 
 TAVI  
(n=799) 
SAVR  
(n=799) 
Standardized differences 
Male sex 427 (53.4%) 434 (54.3%) -0.018 
Age, years 81 [76 – 85] 81 [77 – 85] 0.002 
Income, euros 19659 [18285 – 21971] 19734 [18395 – 22073] -0.060 
Days of hospitalization in the previous year  11 [4 – 23] 10 [4 – 24] -0.006 
Emergency procedure 13 (1.6%) 13 (1.6%) 0.000 
Congestive heart failure 284 (35.5%) 278 (34.8%) 0.016 
Cardiac arrhythmias 420 (52.6%) 427 (53.4%) -0.018 
Pulmonary circulation disorders 63 (7.9%) 76 (9.5%) -0.058 
Peripheral vascular disease 90 (11.3%) 93 (11.6%) -0.012 
Hypertension 350 (43.8%) 338 (42.3%) 0.030 
Chronic pulmonary disease 89 (11.1%) 88 (11.0%) 0.004 
Diabetes 155 (19.4%) 176 (22.0%) -0.065 
Renal disease 122 (15.3%) 119 (14.9%) 0.010 
Liver disease 23 (2.9%) 21 (2.6%) 0.015 
Obesity 71 (8.9%) 62 (7.8%) 0.041 
Myocardial infarction 52 (6.5%) 44 (5.5%) 0.042 
Cerebrovascular disease 69 (8.6%) 79 (9.9%) -0.043 
 
Values are number (%) or median [interquartile range]. 
TAVI = transcatheter aortic valve implantation; SAVR = surgical aortic valve replacement. 
  
26 
 
 
Table 2- Compared clinical outcomes between TAVI and SAVR cohorts 
 
 
Time t 
TAVI (n=799) SAVR (n=799)  
 HRb [CI 95%] p-valueb N  
events 
% [95% CI]a 
N  
events 
% [95% CI]a 
All-cause death 
At 1 year  127 16.8 [14.3 ─ 19.6] 97 12.8 [10.6 ─ 15.4] 1.33 [1.02 ─ 1.72] 0.033 
At 2 years  177 24.2 [21.2 ─ 27.5] 124 16.8 [14.3 ─ 19.7] 1.47 [1.17 ─ 1.84] 0.001 
At 3 years 235 33.7 [30.3 ─ 37.4] 163 23.1 [20.1 ─ 26.4] 1.52 [1.25 ─ 1.85] <0.001 
At 4 years 286 42.8 [39.0 ─ 46.7] 196 29.0 [25.6 ─ 32.6] 1.58 [1.32 ─ 1.89] <0.001 
At 5 years 332 52.4 [48.4 ─ 56.5] 236 37.3 [33.5 ─ 41.4] 1.56 [1.33 ─ 1.84] <0.001 
Postoperative stay in ICU/CCU 
At 1 year  296 37.0 [33.7 ─ 40.4] 537 67.2 [63.8 ─ 70.3] 0.48 [0.43 ─ 0.55] <0.001 
At 2 years  313 39.2 [35.8 ─ 42.5] 540 67.6 [64.2 ─ 70.7] 0.50 [0.45 ─ 0.57] <0.001 
At 3 years 326 40.8 [37.4 ─ 44.2] 548 68.6 [65.2 ─ 71.7] 0.51 [0.46 ─ 0.57] <0.001 
At 4 years 334 41.8 [38.4 ─ 45.2] 550 68.8 [65.5 ─ 71.9] 0.52 [0.46 ─ 0.58] <0.001 
At 5 years 340 42.6 [39.1 ─ 45.9] 556 69.6 [66.3 ─ 72.6] 0.52 [0.46 ─ 0.58] <0.001 
Reoperation 
At 1 year  15 1.9 [1.1 ─ 3.0] 7 0.9 [0.4 ─ 1.7] 2.15 [0.87 ─ 5.30] 0.097 
At 2 years  16 2.0 [1.2 ─ 3.2] 7 0.9 [0.4 ─ 1.7] 2.29 [0.94 ─ 5.60] 0.069 
At 3 years 16 2.0 [1.2 ─ 3.2] 8 1.0 [0.5 ─ 1.9] 2.01 [0.85 ─ 4.71] 0.110 
At 4 years 17 2.1 [1.3 ─ 3.3] 9 1.1 [0.6 ─ 2.1] 1.90 [0.84 ─ 4.28] 0.123 
At 5 years 18 2.3 [1.4 ─ 3.5] 9 1.1 [0.6 ─ 2.1] 2.01 [0.90 ─ 4.50] 0.090 
Stroke 
At 1 year  19 2.4 [1.5 ─ 3.6] 7 0.9 [0.4 ─ 1.7] 2.73 [1.14 ─ 6.53] 0.024 
At 2 years  26 3.3 [2.2 ─ 4.7] 16 2.0 [1.2 ─ 3.2] 1.64 [0.87 ─ 3.08] 0.124 
At 3 years 40 5.0 [3.6 ─ 6.7] 23 2.9 [1.9 ─ 4.2] 1.76 [1.05 ─ 2.94] 0.031 
At 4 years 47 5.9 [4.4 ─ 7.7] 27 3.4 [2.3 ─ 4.8] 1.76 [1.10 ─ 2.84] 0.020 
At 5 years 55 6.9 [5.3 ─ 8.8] 34 4.3 [3.0 ─ 5.8] 1.64 [1.07 ─ 2.54] 0.025 
Myocardial infarction 
At 1 year  5 0.6 [0.2 ─ 1.4] 1 0.1 [0.0 ─ 0.7] 5.01 [0.58 ─ 42.94] 0.142 
At 2 years  13 1.6 [0.9 ─ 2.7] 4 0.5 [0.2 ─ 1.2] 3.27 [1.06 ─ 10.06] 0.039 
At 3 years 17 2.1 [1.3 ─ 3.3] 6 0.8 [0.3 ─ 1.6] 2.86 [1.12 ─ 7.27] 0.028 
At 4 years 19 2.4 [1.5 ─ 3.6] 8 1.0 [0.5 ─ 1.9] 2.39 [1.04 ─ 5.50] 0.039 
At 5 years 25 3.1 [2.1 ─ 4.5] 11 1.4 [0.7 ─ 2.4] 2.30 [1.12 ─ 4.69] 0.023 
Pacemaker 
At 1 year  116 14.5 [12.2 ─ 17.1] 39 4.9 [3.5 ─ 6.5] 3.19 [2.23 ─ 4.56] <0.001 
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At 2 years  125 15.6 [13.2 ─ 18.3] 48 6.0 [4.5 ─ 7.8] 2.80 [2.01 ─ 3.91] <0.001 
At 3 years 137 17.1 [14.6 ─ 19.8] 60 7.5 [5.8 ─ 9.5] 2.47 [1.82 ─ 3.35] <0.001 
At 4 years 156 19.5 [16.9 ─ 22.3] 70 8.8 [6.9 ─ 10.9] 2.42 [1.82 ─ 3.22] <0.001 
At 5 years 163 20.4 [17.7 ─ 23.3] 74 9.3 [7.4 ─ 11.4] 2.40 [1.81 ─ 3.17] <0.001 
 
 
 
TAVI = transcatheter aortic valve implantation; SAVR = surgical aortic valve replacement 
 
a Cumulative probability of event [95% CI] at time t from the nonparametric (1- Kaplan-Meier) estimator for all-cause death; and from the nonparametric Cumulative 
Incidence Functions estimator using competing risk of death for the other outcomes. 
b Hazard Ratios (instantaneous rate of event for TAVI relative to SAVR at any time t) [95% CI] and p-value, estimated between time 0 and time t, from Cox proportional 
hazards model for all-cause death; and from Fine and Gray’s competing risk model for the other outcomes. Matched-pairs design was taken into account with robust variance 
estimator. 
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Table 3- Compared health care utilization outcomes between TAVI and SAVR cohorts  
 
 
Time t 
TAVI (n=799) SAVR (n=799) 
Rate Ratio  
[95% CI] a 
p-valuea 
Total number 
 of health care 
utilization 
Total follow-
up (PY) 
Mean cumulative  
number per persona  
Total number 
 of health care 
utilization 
Total follow-up 
(PY) 
Mean 
cumulative 
number  
per persona 
Number of hospitalization stays  
At 1 year  3184 703.61 4.51 3719 724.11 5.10 0.88 [0.72 ─ 1.09] 0.255 
At 2 years  4374 1349.18 6.46 5478 1411.32 7.71 0.84 [0.64 ─ 1.10] 0.200 
At 3 years 5526 1946.03 8.50 7222 2069.87 10.42 0.82 [0.60 ─ 1.11] 0.192 
At 4 years 6843 2480.04 11.02 8641 2689.18 12.81 0.86 [0.61 ─ 1.20] 0.381 
At 5 years 7769 2969.54 13.07 10097 3272.01 15.39 0.85 [0.60 ─ 1.21] 0.368 
Number of days of hospitalization  
At 1 year  35809 703.61 50.04 43040 724.11 58.16 0.86 [0.79 ─ 0.94] 0.001 
At 2 years  45028 1349.18 65.05 51836 1411.32 71.20 0.91 [0.83 ─ 1.01] 0.071 
At 3 years 53527 1946.03 80.36 61474 2069.87 86.17 0.93 [0.84 ─ 1.03] 0.177 
At 4 years 61887 2480.04 97.23 70014 2689.18 100.72 0.97 [0.87 ─ 1.07] 0.514 
At 5 years 68434 2969.54 112.02 79378 3272.01 116.93 0.96 [0.86 ─ 1.07] 0.432 
Costs  
At 1 year  30774212 703.61 42238 26604033 724.11 35128 1.20 [1.13 ─ 1.28] <0.001 
At 2 years  35123650 1349.18 49330 30183988 1411.32 39917 1.24 [1.15 ─ 1.33] <0.001 
At 3 years 39051054 1946.03 56102 34014554 2069.87 45031 1.25 [1.15 ─ 1.35] <0.001 
At 4 years 42295035 2480.04 62992 37295324 2689.18 50107 1.26 [1.15 ─ 1.37] <0.001 
At 5 years 44889719 2969.54 69083 40860170 3272.01 55687 1.24 [1.13 ─ 1.36] <0.001 
 
 
 
 
TAVI = transcatheter aortic valve implantation; SAVR = surgical aortic valve replacement; PY=Person-year.aFrom GEE Poisson regression model. 
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Table 4- Summary of studies identified in our literature search 
Author/stud
y name 
Inclusion 
period 
Country  Centers 
Sample 
size 
Method of 
comparison 
STS  
(%) 
Logistic 
Euroscore 
I (%) 
All cause death 
1 year  2 years  3 years  4 years 5 years 
TAVI SAVR TAVI SAVR TAVI SAVR TAVI SAVR TAVI SAVR 
High-risk patients 
Partner 1 13, 29, 
30 
2007-2009 >USA 25 348/351 
RCT 
11.8/11.7 29.3/29.2 
24.2% 26.8% 33.9% 35.0% 
/ / 
67.8% 62.4% 
p=0.44 p=0.78 p=0.76 
US Corevalve 
7, 12, 31 
2011-2012 USA 45 391/359 7.3/7.5 17.6/18.4 
14.2% 19.1% 22.2% 28.6% 32.9% 39.1% 
/ / 
p=0.04 p=0.04 p=0.068 
Latib et al. 14 
2003–2008  
+ 2007–
2011 
Italy 1 111/111 
PSM 
4.6/4.6 23.2/24.4 
6.4% 8.1% 
/ / / / 
p=0.80 
Piazza et al.10 2006-2010 3 in EU 3 405/405 / 17.1/17.5 
17.5%
** 
16.5%*
* / / / / 
p=0.93 
Johansson et 
al. 16 
1999-2014 Sweden 1 166/125 / 23/20 
19.5% 10.4% 
/ / 
48.2% 27.% 
/ 
p=0.001 p=0.001 
Muneretto et 
al. 15 
2007-2014 EU 7 204/204 8.2/8.4 19.5/19.2 
9.9% 3.3% 20.5% 8.7% 
/ / / 
p<0.001 p<0.001 
Our study 2010 France 
27 
(nationwi
de) 
832/832 / / 
15.7% 13.8% 22.8% 17.4% 32.5% 22.3% 42.0% 29.5% 51.5% 36.2% 
p=0.326 p=0.021 p<0.001 p<0.001 p<0.001 
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Intermediate-risk patients 
Notion 17 18 2009-2013 Denmark 3 145/135 
RCT 
2.9/3.1 8.4/8.9 
4.9% 7.5% 8.0% 9.8% 
/ / / 
p=0.38 p=0.54 
Partner 25 2011-2013 USA 57 1011/1021 5.8/5.8 / 
12.3% 12.9% 16.7% 18.0% 
/ / / 
p=0.69 p=0.45 
Surtavi19 2012-2016 
USA, 
Europe, 
Canada 
87 879/867 4.4/4.5 11.9/11.6 
6.7% 6.8% 12.6% 14.0% 
/ / / 
NS NS 
Schymik et 
al.9 
2007-2012 Germany 1 216/216 
PSM 
/ 8.7/8.8 
11.6% 7.4% 17.1% 9.7% 19.9% 14.3% 
/ / 
p=0.157* p=0.157* p=0.157* 
Rosato et al.20 2010-2012 Italy 
93 
(nationwi
de) 
355/355 / 6.3/6.3 
11.4% 7.8% 19.6% 12.8% 28.0% 16.6% 
/ / 
p=0.0075* p=0.0075* p=0.0075* 
Thourani et 
al.21 
2011- 2013  
+ 2014  
USA, 
Canada 
51 + 57 1077/944 PSS 5.2/5.4 / 
7.4% 13.0% 
/ / / / 
p=0.0003 
TAVI = transcatheter aortic valve implantation; SAVR = surgical aortic valve replacement; RCT = randomized controlled trial; PSM = Propensity-Score Matching; PSS = 
Propensity-Score Stratification. * calculated over the 3 year period      ** estimated from the number of deaths stated in the manuscript (71 in TAVI, 67 in SAVR)    
 
